As an investor in CUV as well the past year was nothing short than ridiculous (in a good way). Within almost it year its a ~250% increase. If we see a similar development then it will take roughly four years for PAR to reach CUV's SP. I frankly think it wont be that long. The global need is much greater for an alternate arthritis cure. CUV is still waiting on its FDA approval. If revenue is generated within this year that will be a huge de-risk. Phase 3 trail may or may not be applicable, if we have a chance of skipping it because of ethical reasons... gives me goosebumps
As an investor in CUV as well the past year was nothing short...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.005(1.75%) |
Mkt cap ! $99.69M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $3.125K | 10.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16109 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 32600 | 2 |
View Market Depth
| Last trade - 10.32am 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
29.0¢ |
Change
0.005 ( 1.75 %) |
||||
| Open | High | Low | Volume | ||
| 29.0¢ | 29.0¢ | 29.0¢ | 700 | ||
| Last updated 10.18am 02/05/2024 ? | |||||
| PAR (ASX) Chart |